Gliclazide and Joint effusion - a phase IV clinical study of FDA data

Summary:

Joint effusion is reported as a side effect among people who take Gliclazide (gliclazide), especially for people who are male, 50-59 old, also take Cosentyx, and have Ankylosing spondylitis.

The phase IV clinical study analyzes which people have Joint effusion when taking Gliclazide. It is created by eHealthMe based on reports of 27,903 people who have side effects when taking Gliclazide from the FDA, and is updated regularly.

What is Gliclazide?

Gliclazide has active ingredients of gliclazide. It is often used in diabetes. eHealthMe is studying from 28,131 Gliclazide users. Check the latest studies of Gliclazide.

What is Joint effusion?

Joint effusion (presence of extra fluid in joint covering) is found to be associated with 872 drugs and 750 conditions by eHealthMe. Check the latest studies of Joint effusion.

On Jul, 14, 2026

27,903 people reported to have side effects when taking Gliclazide.
Among them, 15 people (0.05%) have Joint effusion.

Among these 15 people:

What is the gender of people who have Joint effusion when taking Gliclazide? *

female: 40 %
male: 60 %

What is the age of people who have Joint effusion when taking Gliclazide? *

What are other drugs people take besides Gliclazide? *

What are other side effects people have besides Joint effusion? *

Pain: 12 people, 80.00%
Joint Pain: 10 people, 66.67%
Psoriasis (immune-mediated disease that affects the skin): 10 people, 66.67%
Drug Ineffective: 9 people, 60.00%
Ankylosing Spondylitis (type of arthritis affecting the spine): 8 people, 53.33%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 8 people, 53.33%
Hypersensitivity: 6 people, 40.00%
Back Pain: 5 people, 33.33%
Gait Disturbance: 5 people, 33.33%
Joint Swelling: 5 people, 33.33%

What are the existing conditions these people have? *

Ankylosing Spondylitis (type of arthritis affecting the spine): 8 people, 53.33%
Psoriasis (immune-mediated disease that affects the skin): 6 people, 40.00%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 5 people, 33.33%
Pain: 3 people, 20.00%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 13.33%
Prostate Cancer: 1 person, 6.67%
Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Gliclazide and have Joint effusion?

- Check whether Joint effusion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gliclazide:

Gliclazide (28,131 reports)

Joint effusion treatments and more:

Joint effusion (9,947 reports)

Browse all side effects of Gliclazide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Joint effusion:

Joint effusion (872 drugs)

Browse all the conditions that are associated with Joint effusion:

Joint effusion (750 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on gliclazide (the active ingredients of Gliclazide) and Gliclazide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.